NeoGenomics, Inc. (NASDAQ:NEO) Stake Lessened by US Bancorp DE

US Bancorp DE decreased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 29.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,815 shares of the medical research company’s stock after selling 763 shares during the period. US Bancorp DE’s holdings in NeoGenomics were worth $27,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. acquired a new stake in shares of NeoGenomics in the first quarter valued at $1,894,000. Bellevue Group AG bought a new stake in NeoGenomics in the first quarter worth about $14,872,000. First Light Asset Management LLC lifted its holdings in NeoGenomics by 14.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after acquiring an additional 480,396 shares during the last quarter. Blue Trust Inc. boosted its position in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 987 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of NeoGenomics by 152.6% in the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock worth $3,658,000 after purchasing an additional 159,350 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on NEO shares. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Wednesday, November 6th. Stephens reissued an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Benchmark reaffirmed a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research report on Tuesday, September 24th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $20.25.

NeoGenomics Price Performance

NEO opened at $15.01 on Tuesday. NeoGenomics, Inc. has a 12-month low of $12.77 and a 12-month high of $21.22. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $1.93 billion, a P/E ratio of -24.66 and a beta of 1.19. The stock has a fifty day moving average of $14.67 and a 200-day moving average of $14.82.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.06) EPS. Equities analysts forecast that NeoGenomics, Inc. will post -0.17 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.